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ABSTRACT
Objective: To test the applicability of the Arbeitsgemeinschaft Gynäkologische Onkologie 
(AGO) and Memorial Sloan Kettering (MSK) criteria in predicting complete cytoreduction 
(CC) in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian 
cancer (ROC).
Methods: Data of consecutive patients undergoing SCS were reviewed. The 
Arbeitsgemeinschaft Gynäkologische Onkologie OVARian cancer study group (AGO-OVAR) 
and MSK criteria were retrospectively applied. Nomograms, based on AGO criteria, MSK 
criteria and both AGO and MSK criteria were built in order to assess the probability to achieve 
CC at SCS.
Results: Overall, 194 patients met the inclusion criteria. CC was achieved in 161 (82.9%) 
patients. According to the AGO-OVAR criteria, we observed that CC was achieved in 87.0% 
of patients with positive AGO score. However, 45 out of 71 (63.4%) patients who did not 
fulfilled the AGO score had CC. Similarly, CC was achieved in 87.1%, 61.9% and 66.7% of 
patients for whom SCS was recommended, had to be considered and was not recommended, 
respectively. In order to evaluate the predictive value of the AGO-OVAR and MSK criteria we 
built 2 separate nomograms (c-index: 0.5900 and 0.5989, respectively) to test the probability 
to achieve CC at SCS. Additionally, we built a nomogram using both the aforementioned 
criteria (c-index: 0.5857).
Conclusion: The AGO and MSK criteria help identifying patients deserving SCS. However, 
these criteria might be strict, thus prohibiting a beneficial treatment in patients who do not 
met these criteria. Further studies are needed to clarify factors predicting CC at SCS.
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INTRODUCTION
Ovarian cancer is considered one of the most lethal malignancies in developed countries, 
due to its high death to incidence ratio [1]. In the United States, more than 22,400 newly 
diagnosed cases and 14,000 cancer-related deaths are estimated, every year [1].
Recurrence rate after primary treatment is high, reaching 75%–80% across different series 
despite recent improvements in primary treatments [2-4]. The mainstay of treatment for 
patients with recurrent ovarian cancer (ROC) is chemotherapy [2-4]. However, accumulating 
data support that secondary cytoreductive surgery (SCS) might have a role in a selected 
population of ROC [5-7]. Since the pioneeristic report from Berek et al. [8], reporting 
outcomes of 32 patients having SCS for ROC, several studies investigated the role of SCS 
in this cluster of patients, highlighting the importance of complete cytoreduction (CC) at 
SCS [8]. However, CC is not achievable in all cases, thus making SCS deleterious and delay 
chemotherapeutic treatments. Therefore, a correct patient selection is paramount to identify 
patients at high probability of having CC, thus reducing a number of ineffective surgeries for 
patients who are likely to have residual disease (RD).
Various models have been built [9-14]. The Arbeitsgemeinschaft Gynäkologische Onkologie 
Descriptive Evaluation of preoperative Selection KriTeria for OPerability in recurrent 
OVARian cancer (AGO DESKTOP OVAR) I trial showed that patients having CC for ROC 
had median overall survival (OS) of 45 months compared with 19 months in patients with 
incomplete cytoreduction [9]. This study suggested that CC was assumed if 3 factors were 
present: 1) no RD at first surgery; 2) good performance status; and 3) absence of ascites. 
The AGO DESKTOP OVAR II prospectively validated this score [12]. The “Memorial Sloan 
Kettering (MSK) criteria” are useful as well in predicting CC [13]. These criteria are based on 
the site of recurrence (i.e., single, multiple, and carcinomatosis) and disease-free interval 
(DFI) [2,13]. However, as suggested by Cowan et al. [2], some criteria might be strict, thus 
excluding patients from the opportunity of having successful surgical procedures for ROC.
In the present paper we sought to evaluate predictors of CC at SCS, building a reliable model 
to allow the selection of patients for SCS. As secondary endpoint we aimed to externally 
validate the Arbeitsgemeinschaft Gynäkologische Onkologie OVARian cancer study group 
(AGO-OVAR) and MSK criteria for surgical resectability.
MATERIALS AND METHODS
1. Patients
We conducted a single institution cohort study that was approved by the National Cancer 
Institute Institutional Review Board (approval number: INT/6812). This is a retrospective 
evaluation examining the role of SCS in a series of consecutive patients with ROC undergoing 
surgery. From January 1, 2001 through December 31, 2015, 199 patients presenting with ROC 
were surgically managed at National Cancer Institute of Milan (Italy). We excluded 5 women 
(2.5%) who did not provide consent to use their medical information for research purposes. 
All the included patients signed written consent for research purpose.
Since the endpoint of this study was to evaluate predictors of CC at SCS and validate AGO-
OVAR and MSK criteria, we searched medical records of patients undergoing SCS in order 
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to analyze outcomes. The computerized surgical database, containing data on every surgical 
procedure performed for patients enrolled into the study was of research quality and had 
been updated by trained residents and nurses. Individual records were screened in order to 
identify baseline patients' and diseases' characteristics. Inclusion criteria were: 1) age ≥18 
years; 2) histologically-proven recurrence of invasive epithelial ovarian, primary peritoneal 
and fallopian tube cancer (i.e., ROC); and 3) execution of SCS. Exclusion criteria were: 1) 
consent withdrawn; 2) absence of gross disease at the time of SCS; and 3) performance status 
not allowing surgical treatment. Central pathology review was performed in all cases, before 
having SCS.
The primary goal of SCS was to achieve CC of the ROC. Over the study period the majority 
of patients had open abdominal procedures; while laparoscopic approach was reserved in 
selected cases and just for patients with single retroperitoneal ROC. Details of our surgical 
protocol are reported elsewhere [15]. Generally, SCS was offered to patients with recurrent 
disease with a DFI longer than 6 months. DFI was the time between the end of platinum-
based adjuvant chemotherapy and the diagnosis of recurrence. Although no specific 
guidelines are available for the section to SCS, a surgical attempt was offered after the 
evaluation of the parameters included in both the AGO-OVAR and MSK criteria: 1) no RD at 
first surgery; 2) good performance status; 3) absence of ascites; 4) site of recurrence; and 5) 
DFI. According to the AGO-OVAR criteria, ascites was recorded when free fluid was 500 mL 
or more. The diagnosis of carcinomatosis included the presence of diffuse peritoneal spread 
of the disease, into multiple anatomical sites.
Generally, preoperative workup included physical examination, dosage of serum markers 
and the execution of evaluation of the diffusion of the recurrent disease via computed 
tomography (CT) scan or positron emission tomography (PET). Magnetic resonance 
imaging (MRI) was executed only in cases of suspicious invasion of the structures 
surrounding the tumor.
2. Statistical methods
Data were summarized using standard descriptive statistics. Univariate logistic regressions 
were performed to evaluate the association between predicting variables and CC. All variables 
with a p-value ≤0.10 were included in a multivariate unconditional logistic regression model. 
Correspondent odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. 
Nomograms were created to improve the clinical interpretation of predicted probability 
of CC at SCS due to different parameters based on AGO-OVAR criteria, MSK criteria 
and both. Particularly, multivariate logistic regression was used to build the nomograms 
considering the variables: Eastern Cooperative Oncology Group (ECOG) performance 
status, RD at primary surgery and ascites (first nomogram), site of recurrence and DFI 
(second nomogram), and all variables together (third nomogram). Performance testing of 
the nomograms developed here was assessed in terms of discrimination (Harrell's c-index). 
C-index provides an estimate of the probability that the model will correctly identify patients 
with ROC who had CC at SCS.
In all presented analyses, the MSK criteria were modified subdividing sites of recurrence 
in 4 categories. In addition to the 3 standard categories of single site, multiple sites, and 
carcinomatosis, we added the variable “retroperitoneal” that is generally associated with 
better prognosis than the others. Furthermore, for analysis purpose, we categorized DFI in 2 
intervals: <12 and ≥12 months.
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OS in patients with and without CC was represented using Kaplan-Meier curves and the 
log-rank test was used to compare the risk of death over the time between the 2 groups of 
patients. Cox univariate and multivariate regression models were performed to evaluate OS in 
study population accordingly to predict variables based on AGO-OVAR criteria, MSK modified 
criteria, and CC. Statistical significance was set to the conventional p-value ≤0.05, with the 
exception of the univariate analyses (significant p≤0.10). Statistical analyses were performed 
using GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA), IBM-Microsoft 
SPSS (SPSS Statistics version 20.0; International Business Machines Corporation [IBM], 
Armonk, NY, USA), R software (version 3.2.3; R Foundation for Statistical Computing, Vienna, 
Austria), and SAS software (version 9.4; SAS Institute, Cary, NC, USA).
RESULTS
Overall 194 patients met the inclusion criteria and were evaluated in order to identify 
predictors of CC. Table 1 reports baseline patients' characteristics. Mean (±standard 
deviation [SD]) patients' age was 61.7 (±12.6) years. Mean (±SD) DFI was 43.9 (±38.5) months. 
International Federation of Gynecology and Obstetrics (FIGO) stage at primary diagnosis 
was stage I, II, III, and IV in 5 (2.6%), 9 (4.6%), 139 (71.6%), and 21 (10.8%) patients, 
respectively. No clear information about stage of disease at presentation were available for 
20 (10.2%) patients. Primary diagnosis was high-grade serous, low-grade serous, mucinous, 
endometrioid, clear cells, and undifferentiated histology in 140 (72.2%), 4 (2.0%), 2 (1%), 19 
(9.8%), 9 (4.6%), and 20 (10.4%), respectively.
Forty-two (21.6%) patients had RD at primary surgery. At the time of SCS 39 (20.1%), 62 
(31.9%), 77 (39.7%), and 16 (8.3%) were diagnosed with retroperitoneal, single peritoneal, 
multiple peritoneal, and carcinomatosis, respectively. Twenty-three (11.8%) patients had 
ascites at the time of SCS. Among those, 7 (3.6%), 9 (5.6%), and 7 (3.6%) patients were 
classified with single peritoneal disease, multiple peritoneal disease and carcinomatosis.
Open surgery was the primary approach in 172 (88.7%) patients, while 22 (11.3%) patients 
had laparoscopic exploration. Conversion to open surgery occurred in 9 (4.6%) cases, while 
laparoscopic cytoreduction was performed in 13 (6.7%) patients. CC was achieved in 161 
(82.9%) out of 194 patients having SCS. According to the AGO-OVAR criteria, we observed 
that CC was achieved in 87.0% of patients who met the 3 criteria. However, 45 out 66 patients 
who did not fulfill the AGO criteria had CC. Of note, 3 out of 4 (75%) women who did not 
meet any criteria (no complete resection, ECOG >0 and ascites) had complete resection 
(Supplementary Table 1).
Supplementary Table 2 reports data about modified MSK criteria in our population. We 
observed that 87.1% (n=142/163) of women for whom SCS was recommended had CC at SCS 
and 61.1% (n=11/18) of patients for whom SCS was considered had CC. Furthermore, 2 out of 
3 (66.7%) patients for whom SCS was not recommended had CC.
Table 2 reports uni- and multivariate analyses evaluating factors predicting CC at SCS. At 
univariate analyses, histotype, RD at primary cytoreductive surgery, presence of ascites 
and DFI were associated with the probability to have CC at SCS (p=0.019, 0.037, 0.086, and 
0.019, respectively). At multivariate analysis, no factors were associated with CC even if 
undifferentiated histotype seemed to have a borderline trend towards lower CC probability.
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Fig. 1 shows survival curves for patients with and without CC. Patients with CC had OS 
significantly higher than patients without CC (p<0.001), with median survival time of 40.5 
and 23 months, respectively.
Looking at OS in Supplementary Table 3, we observed that patients with CC at SCS had lower 
probability to die than patients without CC at SCS (hazard ratio [HR]=0.25; 95% CI=0.16–
0.40; p<0.001). RD and site of recurrence were significantly associated with an increase 
5/11https://ejgo.org https://doi.org/10.3802/jgo.2018.29.e40
Secondary cytoreduction in recurrent ovarian cancer
Table 1. Main characteristics of the study population
Characteristics Value
Age (yr)
Mean (SD) 61.6 (±12.5)
Median (quartiles*) 63.0 (53, 71)
BMI (kg/m2)
Mean (SD) 24.7 (±4.2)
Median (quartiles*) 25.4 (20, 36)
ECOG performance status
0 151 (77.8)
1 43 (22.2)
CA125 at first diagnosis (UI/L)
Mean (SD) 328.5 (±682.2)
Median (quartiles*) 103 (42, 234.3)
Type of ovarian cancer
High-grade serous 140 (72.5)
Low-grade serous 4 (2.0)
Endometrioid 19 (9.8)
Clear cells 9 (4.6)
Undifferentiated 20 (10.3)
Mucinous 2 (1.0)
FIGO stage
I 5 (2.6)
II 9 (4.6)
III 139 (72.7)
IV 21 (10.8)
Unknown 20 (10.3)
RD
No macroscopic tumor at the end of 
surgery (RD=0)
146 (75.2)
Macroscopic tumor at the end of surgery 
(RD>0)
42 (21.6)
Unknown 6 (3.1)
Site of recurrent disease
Retroperitoneal 39 (20.1)
Single peritoneal 62 (31.9)
Multiple peritoneal 77 (39.7)
Carcinomatosis 16 (8.3)
Ascites
Yes 23 (11.9)
No 124 (63.9)
Unknown 47 (24.2)
DFI, (mo)
Mean (SD) 43.9 (±38.5)
Median (quartiles*) 32.5 (18, 59.5)
Follow-up (mo)
Mean (SD) 32.2 (±20.9)
Median (quartiles*) 26 (17, 43.7)
Values are presented as number (%).
BMI, body mass index; CA125, cancer antigen 125; DFI, disease-free interval; ECOG, Eastern Cooperative Oncology 
Group; FIGO, International Federation of Gynecology and Obstetrics; RD, residual disease; SD, standard deviation.
*Quartiles indicates the 25 and 75 percentiles.
in mortality with p-values ≤0.10 even if the only significant site at the univariate analysis 
was carcinomatosis if compared with multiple peritoneal (HR=5.45; 95% CI=2.92–10.18; 
p<0.001). Moreover, although histotype was globally not significant, low-grade serous and 
mucinous types showed a significant association with mortality if compared with high-
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Table 2. Factors predicting complete cytoreduction at the time of secondary cytoreductive surgery
Characteristic Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Age (years)* 1.01 (0.80–1.46) 0.616 - -
BMI (kg/m2)* 0.93 (0.84–1.17) 0.544 - -
ECOG 0.22 -
ECOG 0 Reference -
ECOG 1 0.59 (0.25–1.36) -
Histotype 0.019 0.14
High-grade serous Reference - Reference -
Low grade serous & mucinous 0.31 (0.05–1.83) 0.198 0.45 (0.04–4.85) 0.508
Endometrioid 2.83 (0.36–22.42) 0.325 2.02 (0.23–17.77) 0.525
Clear cells 0.31 (0.07–1.36) 0.122 0.20 (0.03–1.23) 0.083
Undifferentiated 0.24 (0.09–0.65) 0.005 0.29 (0.09–1.00) 0.05
CA125 levels 0.99 (0.99–1.001) 0.266 - -
Stage at presentation N.E. -
I–II Reference -
III–IV N.E. -
RD at primary cytoreductive surgery 0.037 0.239
RD0 Reference Reference
RD>0 0.42 (0.19–0.95) 0.55 (0.20–1.49)
Site of recurrent disease 0.137
Peritoneal multiple site Reference - -
Retroperitoneal 1.78 (0.54–5.87) 0.345 - -
Peritoneal single site 1.06 (0.43–2.60) 0.905 - -
Carcinomatosis 0.34 (0.11–1.10) 0.071
Ascites 0.086 0.138
No Reference Reference
Yes 0.43 (0.16–1.13) 0.44 (0.15–1.31)
Disease-free interval 0.019 0.43
<12 months Reference Reference
≥12 months 3.16 (1.21–8.26) 1.62 (0.49–5.36)
BMI, body mass index; CA125, cancer antigen 125; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; N.E., no estimate; OR, odds ratio; RD, 
residual disease.
*OR per 10-year increase in age and one-unit increase in BMI.
No complete cytoreduction
Complete cytoreduction
Time (mo)
p<0.0010.2
0 24 72
O
S
0.4
0.6
0.8
1.0
12048 96
Fig. 1. OS according to CC at SCS. 
CC, complete cytoreduction; OS, overall survival; SCS, secondary cytoreductive surgery.
grade serous (HR=3.52; 95% CI=1.27–9.73; p=0.015) and due to this, histotype was added to 
the multivariate model. Multivariate analysis confirmed the significance of CC in reducing 
mortality and the positive association of carcinomatosis (HR=3.09; 95% CI=1.53–6.23; 
p=0.002). Low-grade serous and mucinous histology were no longer significant associated 
with OS (p=0.095).
Fig. 2 shows nomogram with ECOG performance status, RD at primary surgery and ascites 
(according to the AGO-OVAR criteria) predicting the probability to have CC; c-index 
was 0.5900. Fig. 3 shows nomogram predicting the probability to have CC based on site 
of recurrence and DFI (according to the modified MSK criteria); c-index was 0.5989. 
Additionally, we built a nomogram using both the aforementioned criteria (Fig. 4). C-index 
for this latter nomogram was 0.5857.
DISCUSSION
The present paper investigated factors predicting CC in a selected population of patients 
with ROC undergoing SCS, thus observing a number of noteworthy findings. First, we 
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Ascites
Yes
No
Residual disease
at primary surgery Yes
No
Points 0 10 20 30 40 50 60 70 80 90 100
0ECOG
performance status 1
0 24022020018016014012010080604020
Total points
Probability of CC (%)
50 60 70 80
c-index=0.5900
Fig. 2. Nomogram displaying the probability of CC according to the variables included in the AGO-OVAR score. 
AGO-OVAR, Arbeitsgemeinschaft Gynäkologische Onkologie OVARian cancer study group; CC, complete cytoreduction; ECOG, Eastern Cooperative Oncology 
Group; RD, residual disease.
DFI
<1 year
>1 years
Points 0 10 20 30 40 50 60 70 80 90 100
Single retroperitonealMultiple peritonealSite of recurrence
Carcinomatosis Single peritoneal
0 18016014012010080604020Total points
Probability of CC (%) 50 60 70 80 90
c-index=0.5989
Fig. 3. Nomogram displaying the probability of CC according to the variables included in the modified MSK criteria. 
CC, complete cytoreduction; DFI, disease-free interval; MSK, Memorial Sloan Kettering.
retrospectively applied the AGO-OVAR and MSK criteria to our population, observing 
that about 87% who met these criteria had CC. However, CC was also obtained in patients 
who did not meet these criteria thus suggesting that SCS should not be denied just on the 
basis of these criteria. Second, CC strongly correlated with OS. Third, our data validated 
the predictive value of AGO-OVAR and MSK criteria. Moreover, we built the first available 
nomograms on these criteria. Fourth, for the first time we built a nomogram that considers 
both the AGO-OVAR and MSK criteria.
Although no mature data supporting SCS in ROC are still available, SCS becomes popular 
due to the growing evidence supporting the beneficial effect of cytoreduction in platinum-
sensitive ROC. The preliminary data of the AGO-OVAR DESKTOP III/ENGOTov20 study 
(presented at ASCO 2017), comparing SCS vs. second line chemotherapy, suggested that in 
selected patients (DFI >6 months and with a positive AGO score) SCS resulted in a clinically 
meaningful increase of progression-free survival and platinum-free interval in comparison 
with chemotherapy alone [16]. However, data on OS are not mature, and the estimated 
primary completion date is December 2019. The ongoing Gynecologic Oncology Group 
(GOG) #213 trial and the Dutch SOCceR trial have similar objectives [17,18].
In agreement with other retrospective experiences [2-7], our investigation supported that 
CC at SCS improves survival. In fact, the complete removal of the tumor is associated with 
improved OS and reduced chemo-resistance [19-21]. A meta-analysis of 40 investigations 
including more than 2,000 women with ROC, suggested that each 10% increase in the 
proportion of patients with CC at SCS was associated with 3 months increase in OS [22].
Once again, our study validated the AGO-OVAR criteria [9,19]. Moreover, we externally 
validated the MSK criteria [2,13]. Other models for patient's selection have been proposed 
(including Tian model, SeC-Score and the Minaguchi criteria) [4,11,14]. Among those, 
the Tian model is the only one that received external validation [14]. However, this latter 
model is characterized by a high-false negative rate [2]. Tian model and SeC-Score include 
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Points 0 10 20 30 40 50 60 70 80 90 100
DFI
<1 year
>1 years
Site of recurrence
Carcinomatosis
0 240160 180 200 22014012010080604020
Total points
Probability of CC (%)
30 40 50 60 70 80 90
c-index=0.58565
Ascites
Yes
No
Residual disease
at primary surgery Yes
No
0ECOG
performance status 1
Single retroperitonealMultiple peritoneal
Single peritoneal
Fig. 4. Nomogram displaying the probability of CC according to the variables included in the AGO-OVAR score and MSK modified criteria. 
AGO-OVAR, Arbeitsgemeinschaft Gynäkologische Onkologie OVARian cancer study group; CC, complete cytoreduction; DFI, disease-free interval; ECOG, Eastern 
Cooperative Oncology Group; MSK, Memorial Sloan Kettering; RD, residual disease.
the evaluation of blood markers (i.e., cancer antigen 125 [CA125] and human epididymis 
protein 4 [HE4]) that are not always available (CA125 levels help in identify ROC in less 
than 50% of cases [11,14]), depend on position of the recurrent lesions (i.e., peritoneal vs. 
retroperitoneal) and to histological features of the relapse (high-grade serous recurrent 
diseases are more likely to be associated with high CA125 and HE4 levels than ROC with 
clear cell histology).
Interestingly, van de Laar et al. [19], tested the performance of 2 prediction models, the 
AGO-OVAR criteria and the Tian model, in order to validate them. The authors observed that 
the AGO score and Tian model showed a positive predictive value for complete SCS of 82.0% 
and 80.3%, respectively, and a false negative rate of 68.5% and 55.6%, respectively [19]. The 
MSK criteria had similar ability in identify patients who had CC at SCS. However, even these 
criteria are too strict, thus prohibiting patients from beneficial SCS. In fact, albeit these 
models can identify patients with a high likelihood of CC at SCS, most patients with negative 
scores might have CC at SCS.
In our paper, we did not propose another inclusion/exclusion criteria model for SCS, but 
we tried to estimate the probability to achieve CC based on the 2 most reliable pre-existing 
criteria models (i.e., AGO-OVAR and MSK criteria). In fact, our nomograms showed that 
a patient with poor performance status (ECOG 1), ascites and who had RD at primary 
surgery has an about 50%–55% of probability to have CC at SCS. Similarly, a patient with 
carcinomatosis and DFI <12 months had about 40%–45% to have CC. Putting together all 
these variables we were able to provide a probability of the beneficial effect of SCS.
The inherent selection biases related to the retrospective study design represent the main 
weakness of the present paper. In fact, our population is a selected population of patients 
selected to undergo SCS. However, the endpoint of the study was not to test the role of SCS in 
ROC and the effectiveness of CC. In fact, we aimed to score the probability to have CC at SCS 
according to both AGO-OVAR and MSK modified criteria, thus helping physicians in identify 
patients who deserve SCS.
Additionally, 2 other points of the present investigation have to be addressed. First, we modified 
the MSK criteria subdividing site of recurrence in 4 categories. In addition to the 3 categories of 
single site, multiple sites, and carcinomatosis, we added the variable “retroperitoneal.” In fact, 
this latter variable is generally associated with better prognosis than the others. Moreover, we 
observed that in our series DFI had a relevant prognostic role especially if we compared patients 
having DFI <12 months with patients having DFI longer than 12 months. Second, although ours 
is a selected population, an expert team of surgeons treated all the patients thus making our 
results not projectable in a setting lacking a high-volume surgical experience.
In conclusion, our investigation evaluated the role of SCS in ROC. In agreement with the 
background, our study confirmed that CC at SCS improves OS. The accuracy of 2 predictive 
models estimating the probability to have CC at SCS was tested. The AGO-OVAR and 
MSK modified criteria were evaluated, thus suggesting that applying these criteria allows 
identification of patients who deserve surgical attempts. However, these criteria alone 
might be strict, thus prohibiting a beneficial treatment in patients who do not meet these 
criteria. Our nomograms might be helpful in estimating the probability of patients to 
have CC based on existing criteria (i.e., AGO-OVAR and MSK). External validations of our 
nomograms are warranted.
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